Vitamin D is essential. VITAL still found no broad prevention benefit

The bottom line

VITAL assigned 25,871 adults to vitamin D3 at 2,000 IU per day or placebo and followed them for a median of 5.3 years. The supplement did not significantly reduce either primary vitamin D outcome: invasive cancer or a composite of myocardial infarction, stroke, and cardiovascular death. (VITAL parent report)

A later VITAL ancillary analysis found 769 total fractures among 12,927 participants assigned vitamin D and 782 among 12,944 assigned placebo: hazard ratio 0.98, 95% confidence interval 0.89–1.08. Nonvertebral and hip fractures were also not significantly lower. (Fracture report)

Why this matters

Vitamin D is required for normal physiology, and a clinically diagnosed deficiency can require treatment. But “an essential nutrient” and “a supplement prevents common age-related disease in already generally healthy adults” are different claims. VITAL tested the second claim. Its null results should not be used to deny the first—or to sell an anti-aging promise that the trial did not support.

What researchers did

The double-blind parent trial enrolled US men aged 50 or older and women aged 55 or older without cancer or cardiovascular disease at baseline. Participants were randomized within a factorial design to vitamin D3 or placebo and marine omega-3 fatty acids or placebo. The vitamin D comparison focused on invasive cancer and major cardiovascular events.

The fracture analysis used centrally adjudicated incident fractures. It did not recruit only people with low vitamin D, osteoporosis, or a high fracture risk, and it did not pair vitamin D with a therapeutic osteoporosis program.

What they found

For invasive cancer, the hazard ratio was 0.96 (95% CI 0.88–1.06). For major cardiovascular events, it was 0.97 (95% CI 0.85–1.12). Neither result was statistically significant. The primary report also did not show significantly lower all-cause mortality.

For fractures, the near-identical event counts and confidence interval around the hazard ratio did not show a preventive benefit. The fracture findings were consistent across total, nonvertebral, and hip fractures.

How strong is the evidence?

Large randomized trials are well suited to detecting average prevention effects while reducing confounding. VITAL's size, blinded design, long follow-up, and clinically meaningful endpoints make its central null results persuasive for people resembling its participants.

That strength is also bounded. A trial of generally healthy adults cannot settle the benefit of correcting a diagnosed deficiency or managing osteoporosis. Baseline status, dose, adherence, co-interventions, and individual clinical needs still matter outside the prevention question VITAL asked.

What this evidence does not show

VITAL does not show that vitamin D is useless, that nobody needs supplementation, or that a clinician should stop treating deficiency. It does not compare every dose, formulation, or high-risk subgroup.

It also did not measure a biological-aging rate, healthspan, or lifespan extension. A broad prevention trial with null cancer, cardiovascular, and fracture outcomes cannot support a general “live longer” claim.

Safety, regulation, and funding

Dietary supplements are not preapproved by the US Food and Drug Administration for safety or effectiveness before sale. A commercial product can also differ from a trial preparation in identity, purity, and labeling. (FDA supplement context)

VITAL was supported primarily by public NIH grants, and Pharmavite donated the vitamin D product. Product donation is a disclosure readers should see; it does not erase the trial's randomized design or independently adjudicated outcomes.

This article is not dosing advice. People with a diagnosed deficiency, bone disease, kidney disease, pregnancy, medication interactions, or other individual concerns should use qualified clinical guidance.

What happens next

Useful future work will keep prevention and treatment populations separate, test clinically meaningful outcomes, and report baseline vitamin D status transparently. For readers, the practical question is not whether vitamin D is “good” or “bad,” but whether evidence from a particular population and endpoint answers their actual question.